AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29804060 — intervention group
Group type: COMPARATOR
Intervention: Present screening plus an HPV test (HPV arm)
Number of subjects: 0
Study 29804483 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum procalcitonin levels
Number of subjects: 0
Study 29804542 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP-HB-Hib booster (Pentabio®)
Number of subjects: 396
Study 29804734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cydar fusion imaging
Number of subjects: 44
Study 29804734 — intervention group
Group type: COMPARATOR
Intervention: Control group (retrospective cohort)
Number of subjects: 44
Study 29804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib with capecitabine 1000 mg/m²
Number of subjects: 60
Study 29804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib with trastuzumab
Number of subjects: 60
Study 29804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib with both capecitabine and trastuzumab
Number of subjects: 60
Study 29804905 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg orally twice a day)
Number of subjects: 60
Study 29805324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amplitude fluctuation
Number of subjects: 169
Study 29805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-amplitude fluctuation
Number of subjects: 169
Study 29805324 — intervention group
Group type: EXPERIMENTAL
Intervention: High, low, and target-range groups
Number of subjects: 169
Study 29805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition-inflammation score (MIS)
Number of subjects: 169
Study 29805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, CRP levels, MIS, and BMI
Number of subjects: 169
Study 29806864 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-Massive Intervention (MMI)
Number of subjects: 186
Study 29807287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for ≥5 days in combination with aspirin 100 mg
Number of subjects: 1805
Study 29807287 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients negative for HBsAg)
Number of subjects: 1805
Study 29807323 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Clinical Decision Support System (CDSS)
Number of subjects: 1000
Study 29807323 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1000
Study 29807323 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS
Number of subjects: 1000
Study 29807396 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8273 300 mg once daily
Number of subjects: 31
Study 29807781 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) co-expressing dominant-negative TGF-βRII (dnTGF-βRII)
Number of subjects: 0
Study 29807781 — intervention group
Group type: COMPARATOR
Intervention: Chimeric antigen receptor (CAR) T cells directed to prostate-specific membrane antigen (PSMA) without dnTGF-βRII (implied control)
Number of subjects: 0
Study 29807885 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified electronic medication administration simulator
Number of subjects: 100
Study 29808092 — intervention group
Group type: EXPERIMENTAL
Intervention: JTTZ formula
Number of subjects: 450
Study 29808092 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET)
Number of subjects: 450
Study 29808308 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (30, 40, or 50 mg) plus gemcitabine (1000 or 1250 mg/m2)
Number of subjects: 0
Study 29808308 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (30, 40, or 50 mg) plus docetaxel
Number of subjects: 0
Study 29808611 — intervention group
Group type: EXPERIMENTAL
Intervention: Current asthma cases (46)
Number of subjects: 237
Study 29812997 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells genetically modified to express CAR targeting BCMA (CAR-BCMA)
Number of subjects: 16
Study 29812996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib plus intensive chemotherapy
Number of subjects: 60
Study 29812996 — intervention group
Group type: COMPARATOR
Intervention: Imatinib plus intensive chemotherapy (from COG AALL0031)
Number of subjects: 60
Study 29842966 — intervention group
Group type: EXPERIMENTAL
Intervention: Trying New Foods Scale
Number of subjects: 233
Study 29842993 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-FOLFOX6 (PULSE trial)
Number of subjects: 248
Study 29842993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX6/FOLFIRI (POSIBA trial)
Number of subjects: 248
Study 29842993 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Panitumumab and Cetuximab)
Number of subjects: 248
Study 29843619 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient empowerment assessed using the SWE-CES-10
Number of subjects: 157
Study 29843619 — intervention group
Group type: EXPERIMENTAL
Intervention: General self-efficacy assessed using EQ5D and Ladder of Life
Number of subjects: 157
Study 29843619 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between patient empowerment and general self-efficacy
Number of subjects: 157
Study 29843619 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regressions on patient empowerment and general self-efficacy
Number of subjects: 157
Study 29843711 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) tests available and in use
Number of subjects: 100
Study 29843711 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) tests requested by clinical staff
Number of subjects: 100
Study 29843711 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific POC tests universally available
Number of subjects: 100
Study 29843711 — intervention group
Group type: EXPERIMENTAL
Intervention: Most requested POC tests
Number of subjects: 100
Study 29843776 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment in AS patients
Number of subjects: 2750
Study 29843776 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment in RA patients
Number of subjects: 2750
Study 29843792 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg intravenously on days 1, 8, and 15 of cycle 1, and on day 1 of cycles 2-8 (24 weeks treatment period)
Number of subjects: 48
Study 29843792 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg intravenously
Number of subjects: 48
Study 29844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated Fat (SAT)
Number of subjects: 38
Study 29844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated Fat (UNSAT)
Number of subjects: 38
Study 29844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrates (CARB)
Number of subjects: 38
Study 29844096 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased intakes of Saturated Fat (SAT)
Number of subjects: 38
Study 29844102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBP)
Number of subjects: 0
Study 29844102 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low energy diet (VLED)
Number of subjects: 0
Study 29844244 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of total protein (highest quartile)
Number of subjects: 2441
Study 29844409 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation during breastfeeding
Number of subjects: 86
Study 29845604 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medical Services intervention for cardiac arrest patients
Number of subjects: 65
Study 29845626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-neutral HPV vaccination (Arm A)
Number of subjects: 11375
Study 29845626 — intervention group
Group type: COMPARATOR
Intervention: HPV vaccination of girls and hepatitis B-virus (HBV) vaccination of boys (Arm B)
Number of subjects: 11375
Study 29845626 — intervention group
Group type: COMPARATOR
Intervention: Gender-neutral HBV vaccination (Arm C)
Number of subjects: 11375
Study 29845744 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 93
Study 29845744 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable gastric band
Number of subjects: 93
Study 29845744 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB and MRI-measured skeletal muscle
Number of subjects: 93
Study 29846328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn device for measuring peripheral AIx (PAIx)
Number of subjects: 254
Study 29846328 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-worn device for measuring central AIx (CAIx)
Number of subjects: 254
Study 29846328 — intervention group
Group type: COMPARATOR
Intervention: Wrist-worn device
Number of subjects: 254
Study 29846848 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy
Number of subjects: 0
Study 29846848 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin + nab-paclitaxel combination therapy
Number of subjects: 0
Study 29847380 — intervention group
Group type: EXPERIMENTAL
Intervention: Triton System (tBL)
Number of subjects: 61
Study 29847380 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravimetric blood loss measurement (gBL)
Number of subjects: 61
Study 29847380 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual blood loss estimation by anesthesiologist (aBL)
Number of subjects: 61
Study 29847380 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual blood loss estimation by obstetrician (oBL)
Number of subjects: 61
Study 29848187 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression scores, greater trauma-related negative cognitions about self, poorer physical health functioning
Number of subjects: 115
Study 29848187 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater trauma-related negative cognitions about self and self-blame, higher level of education, higher depression scores
Number of subjects: 115
Study 29848187 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depression scores, greater trauma-related negative cognitions about self
Number of subjects: 115
Study 29848328 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fragmented adipose tissue injection
Number of subjects: 38
Study 29848396 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dietary intake assessed with two non-consecutive 24 h dietary recalls
Number of subjects: 9218
Study 29848478 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous traditional Chinese medicine (TCM)
Number of subjects: 162
Study 29848494 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids and arachidonic acid measured 1 month after AMI
Number of subjects: 2985
Study 29848494 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis controlling for demographic and clinical characteristics
Number of subjects: 2985
Study 29848736 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation-positive (M+) patients (n=88)
Number of subjects: 575
Study 29848736 — intervention group
Group type: COMPARATOR
Intervention: EGFR mutation-negative patients
Number of subjects: 575
Study 29849651 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (SC-TCZ) 162 mg weekly
Number of subjects: 52
Study 29849841 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics for cancer-related pain
Number of subjects: 465
Study 29849841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician assessment of analgesics
Number of subjects: 465
Study 29849841 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-physician satisfaction
Number of subjects: 465
Study 29850134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 50
Study 29850134 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 50
Study 29850244 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 65
Study 29850244 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 65
Study 29850244 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 65
Study 29850262 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Pittsburgh Sleep Quality Index (shortPSQI)
Number of subjects: 1246
Study 29850262 — intervention group
Group type: COMPARATOR
Intervention: Original Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 1246
Study 29851062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume-guided fluid challenge
Number of subjects: 50
Study 29851062 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive peripheral perfusion index
Number of subjects: 50
Study 29851062 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative complications including mortality
Number of subjects: 50
Study 29851546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg daily until progressive disease/unacceptable toxicity
Number of subjects: 110
Study 29851582 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to particulate matter of less than 10 μm (PM10)
Number of subjects: 281
Study 29851582 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 281
Study 29852037 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) at a dose of 54 Gy delivered in 3 fractions of 18 Gy over 1.5 to 2.0 weeks
Number of subjects: 26
Study 29852037 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 26
Study 29852151 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength and flexibility (SF)
Number of subjects: 154
Study 29852151 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill training (MST)
Number of subjects: 154
Study 29852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition eating behavior subscale
Number of subjects: 107
Study 29852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger eating behavior subscale
Number of subjects: 107
Study 29852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 107
Study 29852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cortisol levels
Number of subjects: 107
Study 29852904 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise and a balanced diet
Number of subjects: 24
Study 29852933 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in combination with optimal medical therapy (OMT)
Number of subjects: 700
Study 29852933 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 700
Study 29852973 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 153078
Study 29852973 — intervention group
Group type: COMPARATOR
Intervention: Other glucose-lowering drugs (GLDs)
Number of subjects: 153078
Study 29853436 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychological screening tool
Number of subjects: 21
Study 29853437 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrive with Me intervention for 5 months
Number of subjects: 400
Study 29853437 — intervention group
Group type: COMPARATOR
Intervention: Weekly newsletter for 5 months (Control)
Number of subjects: 400
Study 29853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab prefilled syringe (PFS)
Number of subjects: 35
Study 29853609 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated-use usability testing
Number of subjects: 35
Study 29853657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept and ganetespib combination treatment
Number of subjects: 5
Study 29853658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus pembrolizumab
Number of subjects: 26
Study 29853852 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with incomplete spinal cord injury
Number of subjects: 20
Study 29853852 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 29854007 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal imaging device (Diabetic Foot Ulcer Prevention System (DFUPS))
Number of subjects: 105
Study 29854007 — intervention group
Group type: COMPARATOR
Intervention: Hand-held infrared spot thermometer (Thermofocus® 01500A3)
Number of subjects: 105
Study 29854007 — intervention group
Group type: COMPARATOR
Intervention: Comparison between thermal imaging device and hand-held thermometer
Number of subjects: 105
Study 29854408 — intervention group
Group type: EXPERIMENTAL
Intervention: NORDIET-FFQ
Number of subjects: 0
Study 29854408 — intervention group
Group type: COMPARATOR
Intervention: HUNT-PAQ
Number of subjects: 0
Study 29854429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with planned foveal detachment technique
Number of subjects: 28
Study 29854429 — intervention group
Group type: COMPARATOR
Intervention: Conventional vitrectomy
Number of subjects: 28
Study 29854429 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreomacular adhesion (VMA) resistant to pharmacotherapy
Number of subjects: 28
Study 29854447 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-based snack bar with added plant stanol ester (1.6 g plant stanols/day)
Number of subjects: 71
Study 29854447 — intervention group
Group type: COMPARATOR
Intervention: Placebo snack bar
Number of subjects: 71
Study 29854923 — intervention group
Group type: COMPARATOR
Intervention: SB742457 15 mg daily
Number of subjects: 1260
Study 29854923 — intervention group
Group type: COMPARATOR
Intervention: SB742457 35 mg daily
Number of subjects: 1260
Study 29854923 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5-10 mg daily)
Number of subjects: 1260
Study 29854923 — intervention group
Group type: EXPERIMENTAL
Intervention: SB742457 as adjunct to donepezil
Number of subjects: 1260
Study 29854922 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care (PDC) program
Number of subjects: 328
Study 29854922 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no PDC)
Number of subjects: 328
Study 29854928 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg once daily
Number of subjects: 274
Study 29854928 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg once daily
Number of subjects: 274
Study 29854928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 29854928 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-126 5 mg once daily
Number of subjects: 274
Study 29854930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hUCB-MSCs (n=3)
Number of subjects: 9
Study 29854930 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hUCB-MSCs (n=6)
Number of subjects: 9
Study 29854930 — intervention group
Group type: EXPERIMENTAL
Intervention: hUCB-MSCs (both doses)
Number of subjects: 9
Study 29854934 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab
Number of subjects: 0
Study 29854933 — intervention group
Group type: EXPERIMENTAL
Intervention: 250-mg rilapladib once daily for 24 weeks
Number of subjects: 124
Study 29854933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 29854935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab treatment
Number of subjects: 0
Study 29854935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29854939 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day memantine plus 24 mg/day galantamine-CR
Number of subjects: 232
Study 29854939 — intervention group
Group type: COMPARATOR
Intervention: 24 mg/day galantamine-CR plus placebo
Number of subjects: 232
Study 29855190 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with comorbid depression (O + D)
Number of subjects: 600
Study 29855190 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients (NON)
Number of subjects: 600
Study 29855190 — intervention group
Group type: COMPARATOR
Intervention: Obese patients without depression (OBESE)
Number of subjects: 600
Study 29855261 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference (NC) in non-SDB population
Number of subjects: 4433
Study 29855261 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck circumference (NC) per unit increase in non-SDB population
Number of subjects: 4433
Study 29855296 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth spacing interventions led by clinical providers and inclusion of spouses
Number of subjects: 46
Study 29855296 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of male partners and knowledgeable health care providers in interventions
Number of subjects: 46
Study 29855752 — intervention group
Group type: COMPARATOR
Intervention: Pump infusion
Number of subjects: 30
Study 29855752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid push infusion
Number of subjects: 30
Study 29855806 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 9 mg/Kg combined with oxaliplatin 130 mg/m2 and capecitabine (dosage not specified)
Number of subjects: 0
Study 29855972 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 1291
Study 29855972 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 1291
Study 29855975 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable contraceptives
Number of subjects: 489
Study 29855975 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 489
Study 29856121 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nomogram based on performance status, liver metastasis, CA19-9 log-value, ANC, and albumin.
Number of subjects: 445
Study 29856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having children
Number of subjects: 70
Study 29856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Active or substituted drug consumption
Number of subjects: 70
Study 29856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake > 20 g/day or history of alcohol abuse
Number of subjects: 70
Study 29856132 — intervention group
Group type: EXPERIMENTAL
Intervention: History of depressive disorder and/or of attempted suicide
Number of subjects: 70
Study 29856132 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drug intake
Number of subjects: 70
Study 29856132 — intervention group
Group type: COMPARATOR
Intervention: Age, gender, country of birth, positive HCV serology, HIV-related factors (AIDS status, use of combination antiretroviral therapy (cART), nadir and current CD4 counts, HIV viral load)
Number of subjects: 70